酸盐和酸盐寡糖的保护作用对困难菌和毒素的保护作用
Maria Eleni Mavrogeni1, Mostafa Asadpoor1, Jo H Judernatz2
1Division of Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, Universiteitsweg 99, 3584 CG Utrecht, The Netherlands.
Toxins
|October 27, 2023
概括
酸盐和酸盐的寡糖会减少Clostridioides difficile的生长,并通过促进紧结重组,保护肠道屏障功能免受TcdA毒素的侵害.
科学领域:
- 微生物学 微生物学
- 胃肠病学 胃肠病学
- 生物化学 生物化学
背景情况:
- 困难菌感染 (CDI) 是一个主要的医疗相关感染.
- 在C.I.C.中, 困难性肠毒素 (TcdA) 通过向Rho-GTPases和细胞骨动力学来破坏肠道屏障的完整性.
- 非消化性寡糖 (NDOs) 正在探索其潜在的健康益处.
研究的目的:
- 评估酸盐寡糖化物 (AOS) 和酸盐寡糖化物 (COS) 对C.的抗病原和屏障保护作用. 困难和TcdA. 这两种.
- 研究AOS和COS对肠上皮细胞完整性和紧结 (TJ) 动态的影响.
主要方法:
- 在C.I.C.中, 艰难的生长抑制试验.
- 使用TCDA治疗的Caco-2细胞进行细胞细胞毒性测定.
- 在Caco-2单层中测量半细胞透率 (TEER,LY流量).
- 免疫光显微镜用于评估TJ蛋白位址 (ZO-1,occludin).
- 开关测定以评估TJ重组.
主要成果:
- 无论是AOS还是COS都显著抑制了C. 艰难的生长. 困难的生长.
- 在24小时内,AOS和COS都没有减弱TcdA诱导的细胞毒性.
- AOS和COS保护Caco-2单层免受TcdA诱导的对细胞通透性的增加.
- AOS和COS防止了TcdA诱导的奥克卢丁错位,并加速了TJ重组.
结论:
- AOS和COS表现出对C的抗病原性质. 困难的. 困难的.
- 通过维护TJ完整性和促进重组,AOS和COS具有对TcdA的屏障保护作用.
- 这些NDO代表了管理CDI相关的肠损伤的潜在治疗剂.
相关概念视频
01:20Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents
223
Diarrhea is characterized by the occurrence of frequent, watery bowel movements. Various factors can trigger diarrhea, including viral or bacterial infections, foodborne illnesses, side effects from certain medications, and underlying digestive disorders. If not adequately managed, diarrhea can lead to complications such as dehydration, electrolyte imbalances, and nutrient deficiencies. Severe diarrhea can lead to significant weight loss, malnutrition, and weakened immune function.
Adsorbents...
Adsorbents...
223
01:17Drugs for Treatment of Diarrhea-Predominant IBS
186
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
186
01:21Drugs for Treatment of Constipation-Predominant IBS
181
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
181
01:14Prevention of Further Absorption of Poison
834
In cases of acute poisoning, the primary objective is to prevent further absorption of the toxic substance into the body. Immediate interventions using various decontamination techniques targeting the gastrointestinal (GI) tract can achieve this. Decontamination is crucial to prevent poison from entering the systemic circulation, which involves washing affected areas with water and mild soap and removing contaminated clothing. Once external decontamination is done, attention must be turned to...
834
01:20Drugs Affecting GI Tract Motility: Other Laxatives
241
Laxatives are primarily used to alleviate constipation, a common gastrointestinal disorder characterized by infrequent bowel movements and difficulty passing stools. They work by various mechanisms to increase the volume or frequency of bowel movements. The primary modes of action of laxatives include increasing stool bulk, softening the stool, stimulating intestinal motility, and osmotically drawing water into the intestines.
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
241
01:24Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
517
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
517